2-[4-[(3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl)amino]-1-piperidyl]thiazole-5-carboxylic acid | 848502-97-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[4-[(3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl)amino]-1-piperidyl]thiazole-5-carboxylic acid
• 英文别名: 2-(4-{[(3,4-Dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}piperidin-1-yl)-1,3-thiazole-5-carboxylic acid；2-[4-[(3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl)amino]piperidin-1-yl]-1,3-thiazole-5-carboxylic acid
• CAS: 848502-97-6
• 化学式: C₁₅H₁₆Cl₂N₄O₃S
• 分子量: 403.289
• InChiKey: DCKPCHMCUFLQER-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  127
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-氯苯甲酰乙腈 、 2-[4-[(3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl)amino]-1-piperidyl]thiazole-5-carboxylic acid 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以78%的产率得到2-(4-[{(3,4-Dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}piperidin-1-yl)-N-methoxy-1,3-thiazole-5-carboxamide
  参考文献：
  名称：

  吡咯酰胺DNA旋转酶抑制剂：抗菌活性和功效的优化

  摘要：

  吡咯酰胺是一类针对DNA促旋酶的新型抗菌剂，DNA促旋酶是一种跨细菌物种的必不可少的酶，抑制作用会破坏DNA的合成，进而导致细胞死亡。通过取代分子的吡咯，哌啶和杂环部分来优化生化活性和其他类似药物的特性，可得到具有改善的细胞活性和体内功效的吡咯酰胺。

  DOI：

  10.1016/j.bmcl.2011.10.010
• 作为产物：
  描述：

  5-甲基-1H-吡咯-2-甲酸乙酯 在 盐酸 、 磺酰氯 、 水 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 、 四氯化碳 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-[4-[(3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl)amino]-1-piperidyl]thiazole-5-carboxylic acid
  参考文献：
  名称：

  吡咯酰胺DNA旋转酶抑制剂：抗菌活性和功效的优化

  摘要：

  吡咯酰胺是一类针对DNA促旋酶的新型抗菌剂，DNA促旋酶是一种跨细菌物种的必不可少的酶，抑制作用会破坏DNA的合成，进而导致细胞死亡。通过取代分子的吡咯，哌啶和杂环部分来优化生化活性和其他类似药物的特性，可得到具有改善的细胞活性和体内功效的吡咯酰胺。

  DOI：

  10.1016/j.bmcl.2011.10.010

文献信息

• Pyrrol derivatives with antibacterial activity
  申请人：Green Morenike Oluyinka

  公开号：US20060223801A1

  公开（公告）日：2006-10-05

  Compounds of Formula (1) and their pharmaceutically acceptable salts are described: Formula (1) Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  本文描述了化学式（1）的化合物及其药用可接受的盐：化学式（1）。同时描述了其制备方法、含有它们的药物组合物、作为药物的用途以及在治疗细菌感染方面的应用。
• [EN] PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY<br/>[FR] DERIVES DE PYRROL A ACTIVITE ANTIBACTERIENNE
  申请人：ASTRAZENECA AB

  公开号：WO2005026149A1

  公开（公告）日：2005-03-24

  Compounds of Formula (1) and their pharmaceutically acceptable salts are described: Formula (1) Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  描述了公式(1)的化合物及其药学上可接受的盐：公式(1)的制备方法、含有它们的药物组成物、它们作为药物的使用以及它们在治疗细菌感染方面的使用也被描述了。
• Optimization of Pyrrolamide Topoisomerase II Inhibitors Toward Identification of an Antibacterial Clinical Candidate (AZD5099)
  作者：Gregory S. Basarab、Pamela J. Hill、C. Edwin Garner、Ken Hull、Oluyinka Green、Brian A. Sherer、P. Brian Dangel、John I. Manchester、Shanta Bist、Sheila Hauck、Fei Zhou、Maria Uria-Nickelsen、Ruth Illingworth、Richard Alm、Mike Rooney、Ann E. Eakin

  DOI：10.1021/jm500462x

  日期：2014.7.24

  AZD5099 (compound 63) is an antibacterial agent that entered phase 1 clinical trials targeting infections caused by Gram-positive and fastidious Gram-negative bacteria. It was derived from previously reported pyrrolamide antibacterials and a fragment-based approach targeting the ATP binding site of bacterial type II topoisomerases. The program described herein varied a 3-piperidine substituent and incorporated 4-thiazole substituents that form a seven-membered ring intramolecular hydrogen bond with a 5-position carboxylic acid. Improved antibacterial activity and lower in vivo clearances were achieved. The lower clearances were attributed, in part, to reduced recognition by the multidrug resistant transporter Mrp2. Compound 63 showed notable efficacy in a mouse neutropenic Staphylococcus aureus infection model. Resistance frequency versus the drug was low, and reports of clinical resistance due to alteration of the target are few. Hence, 63 could offer a novel treatment for serious issues of resistance to currently used antibacterials.
• PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY
  申请人：AstraZeneca AB

  公开号：EP1664025B1

  公开（公告）日：2007-09-19
• JP2007505092A
  申请人：——

  公开号：JP2007505092A

  公开（公告）日：2007-03-08